Background Nivolumab (NIVO) + ipilimumab (IPI) combination demonstrated improved overall survival (OS) benefits vs chemotherapy as first-line treatment for advanced NSCLC in both tumor programmed death ligand 1
And what we saw was a clear survival benefit in favor of the nivolumab, ipilimumab, chemotherapy arm, again a limited course of chemotherapy, with an OS [overall survival] benefit, a hazard ratio of 0.74. In that 3-year update also presented 2 weeks ago at ASCO [American Society of ...
Key secondary endpoints include overall survival (OS) and incidence of adverse events (AEs). Part B of the study is ongoing. About Renal Cell Carcinoma Renal cell carcinoma (RCC) is the most common ...
followed by Opdivo monotherapy 480 mg Q4W) infusion, or single agent lenvatinib or sorafenib as oral capsules in the control arm. The primary endpoint of the trial is overall survival and key secondary endpoints include objective response rate ...
Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung CancerImmunotherapyNSCLCAnti-PD-1Inverse probability of censoring weighting
Phase 2 CheckMate 069 Study Suggests Nivolumab Plus Ipilimumab May Improve Overall Survival in MelanomaJonathan GoodmanMPhilOncology Editor
TFS and survival states for immune checkpoint inhibitor plus tyrosine kinase inhibitor (TKI) combination are of interest.Methods:Overall, 651 patients (pts) with aRCC were randomized to receive 1L NIVO + cabozantinib (CABO) or SUN in the CheckMate 9ER trial; treatment continued until progression ...
P1.12-21 Developing a Real-World 3L Comparator to CheckMate 032: Overall Survival (OS) in Patients with Small Cell Lung Cancer (SCLC)doi:10.1016/j.jtho.2018.08.856L. SchwartzbergB. KorytowskyJ. PenrodY. YuanG. SelvaggiJournal of Thoracic Oncology...